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ABSTRACT
Day-by-day metabolic disorder/syndrome (MS) falling in love with current lifestyle status of everyone especially after study age group of people. 
If we look carefully around us, we will see evidence is growing up of diabetic, obese, and hypertensive population regularly. In urgencies of above 
view extensive literature survey has been done prioritizing prevalence of metabolic disorder and peroxisome proliferator-activated receptor-gamma 
(PPAR-γ) as potential target protein. This review covered current status of MS emphasizing diabetes along with its management criteria. Special 
importance is given to PPAR-γ exploring its metabolic regulation and structural orientation for understanding ligand-protein interaction. Development 
of PPAR-γ agonist thiazolidinediones (TZDs) and other pharmacodynamic importance of this nuclear receptor also discussed. Being as nuclear 
receptor more genomics exploitation needs to be done emphasizing minimization of cardiac adverse effect. Selective PPAR modulator (SPPRM), TZDs 
are the master regulator of adipogenesis and angiogenesis which makes TZD more interesting topic to explore. Developmental hierarchy suggests that 
in a few years from now PPAR-γ won’t be in the list of double edge sword.
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PREVALENCE OF METABOLIC DISORDER
The modern lifestyle of 21st century uplifts the priority of metabolic 
disorder in front of us where there is a high imbalance between intake 
and utilization of calorie. Concentrating on this increasing prevalence, 
multidisciplinary studies aimed at preventing and controlling metabolic 
disorder is a worldwide research priority. Metabolic disorder refers to 
a collection of various interrelated cardiometabolic risk factors that 
leads to the generation and development of cardiovascular dysfunction 
that contributes a major percentage in cardiovascular morbidity and 
mortality. The prevalence and incidence of certain disorders such as 
diabetes, dyslipidemias, obesity, hypertension, and atherosclerosis 
have been well defined in large population globally whether in the 
USA or in Southern Asia especially in India [1-3]. Data revealed that 
the percentage of metabolic syndrome (more than 33%) in the USA 
increasing year by year and affected females more than males on any 
tested age group [4]. On an average, more than 30% of the Southern 
Asian population is in grasp of the same whether they are in the higher 
economic part of society or from lower socioeconomic background [5]. 
Metabolic disorder burden in urban areas of India estimated as ranges 
between 25 and 45% [6]. Among all the diabetes mellitus is of main 
concern which contributed either by insulin resistance or by absolute 
deficiency in insulin secretion [7]. According to the recent estimate of 
American Diabetes Association, there were 30.3 million diabetics in 
2015 in USA and prediabetics were estimated as 84.1 million which 
was 79 million in 2010 [8]. According to the World Health Organization 
estimation worldwide 422 million (8.5% of total population) people 
had diabetes. The global burden of diabetes has been increasing by 
large stair step since past 3 decades and is affecting rapidly in low- and 
middle-income countries [9-11].
MANAGEMENT OF METABOLIC DISORDER
The term “control” suits well than “prevention” when it comes for 
metabolic disorder management as being metabolism is a continuous 
process, and it alters the calorie level in physiological system every 
second. The control measures for the same is always dependent on 
caloric input-output ratio which directly or indirectly emphasize the 
risk factors of atherosclerotic cardiovascular diseases [7,12,13]. The 
stock two approaches managing this condition with great success 
include proper energy management by diet along with physical exercise 
habits first and pharmacological interventions secondly [12-15]. 
Either of those two or combination of them should lower the criteria 
for metabolic syndrome defined by National Cholesterol Education 
Program Adult Treatment Panel [16]. A new treatment strategy using 
designing prebiotics and probiotics with natural food products also 
trying to find a way to control this metabolic disorder [17]. Sometimes 
lifestyle changes are not enough to control the risk factors of metabolic 
syndrome, so doctors generally prescribed pharmacological agents to 
combat the situation which actually contributes the metabolic syndrome 
such as diabetes, dyslipidemia, atherosclerosis, and highpertension. In 
major cases, the treatment proceeds emphasizing diabetes and to the 
lower lipid levels. A diverse number of protein identified for managing 
diabetes such as α-glucosidase, peroxisome proliferator-activated 
receptor-gamma (PPAR-γ) [18,19], sodium glucose cotransporter-2, 
dipeptidyl peptidase-IV, glucokinase, glucagon-like peptide-I [7,20,21], 
adenosine monophosphate activated protein kinase [22], and G protein-
coupled receptor-119 (GPR-119) [23] and so on but PPARs snatching its 
importance as being a target protein for hyperlipidemia also.
PPARS, TARGET FOR METABOLIC DISORDER
The peroxisome proliferator-activated receptor first described 60 years 
back but discovered in the 1990s and named so as the ligands attached 
to this protein can control the proliferation of peroxisome in various 
tissue cells [24]. PPAR regulates biological processes influencing gene 
expression including glucose and lipid metabolism, cell proliferation, 
and inflammation regulation by activating transcription factor of 
targeting cells [25,26]. This receptor works better as agonist rather 
than antagonist and also classified as a full agonist, partial, dual 
agonist, and pan-agonist with other serotypes depending on binding 
and activity [27,28]. Till date, three PPAR subtypes encoded by 
separate genes have been discovered such as PPAR-α, PPAR-β/δ, and 
PPAR-γ [12]. These three isotypes of PPAR [29] distributed in different 
tissues and effective on selective genes and perform different biological 
functions (Table 1) [30-35].
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PPAR-γ AND METABOLIC REGULATION
The PPAR-γ is a nuclear receptor that regulates glucose metabolism 
with two effectors binding site called activation function 1 (AF1) and 
AF2. The receptor’s central deoxyribonucleic acid (DNA) binding 
domain is followed by the C-terminal ligand binding domain (LBD), 
which comprises AF2. PPAR-γ is regulated by a phosphorylation site in 
the LBD at Ser-273 (Ser-245 in the shorter isoform 1) [12]. In recent 
years, PPAR-γ emerged as an attractive target for drug development, 
mainly control the expression of gene networks involved in metabolic 
homeostasis, adipogenesis, lipid metabolism, carcinogenesis and 
inflammation. Fatty acids and eicosanoids are the endogenous ligands 
of PPAR-γ, can be activated by dietary fats and their metabolites, 
act as lipid sensors that, on activation, are able to markedly redirect 
metabolism by ligand-activated transcription factors that bind to more-
or-less specific sequences of the genome and thereby control gene 
expression [36]. In the absence of ligands, PPAR-γ form heterodimer 
with retinoid X receptor (RXR), another nuclear receptor, and helps in 
transcription of target genes by binding to PPAR response elements 
in the promoter region of target genes [37]. Ligands bind at the PPAR, 
particularly at LBD brings the changes in target genome which express 
the final changes in the transcription process. The newly synthesized 
messenger ribonucleic acid (mRNA) travelled to the cytoplasm through 
nuclear pores and express in protein at ribosome to alter several PPAR 
responsible biological events (Fig. 1).
PPAR-γ - Structural insight
First three-dimensional X-ray crystallographic structure of PPAR-γ 
studied in 1998 and since then lots of ligand-based cocrystal structure 
reported in protein data bank [38]. The structure of PPAR-γ composed 
of two prime regions, i.e., DNA binding domain (DBD) and LBD. The DBD 
region of PPAR-γ commonly attached to the peroxisome proliferator 
response elements (PPRE) of DNA sequence in the 5’ end. Here carboxy-
terminal extension of PPAR-γ causes a significant DNA interaction. LBD 
is separated from DBD by two helical segments. RXR heterodimerize 
with PPAR-γ as a fashion that the LBD of PPAR-γ is closely packed 
between DBD and LBD of RXR to keep them separated from each other 
(Fig. 2) [39]. Ligands of PPAR-γ induce a “Y” shaped binding pocket 
where there remains a covalent bond between ligands and amino acid 
Cysteine [40]. Most of the ligands interact with PPAR-γ composed of 
polar head and hydrophobic tail allowing hydrophobic interaction at 
the binding region. Ser-289, His-323, His-449, and Tyr-473 (Fig. 3) 
contributes the important amino acid residues around binding pocket 
that allow hydrogen bonding with carboxylic acids of natural modulators 
or keto group of synthetic agonist thiazolidinediones (TZDs) [41-43].
Historical chronology of PPAR-γ ligands
The first glitazone was introduced by 1990s and since then PPAR-γ 
agonist has emerged as very crucial class of agents to combat insulin 
resistance in humans either with diet or with other class of oral 
hypoglycemics. It was 1995 when TZD moiety proved to have insulin 
sensitivity and first agent troglitazone (TRO) approved by United State 
Food and Drug Administration in 1997 came to consideration [30,44]. 
Although TRO was withdrawn from the market due to safety issues, it 
Table 1: Comparisons of different PPAR subtypes
S. No. PPAR 
subtypes
Tissue distribution 
pattern
Target genes for enzymes Biological function Discovered clinical agents
1. PPAR-α Liver
Heart
Muscles
Kidney
Carnitine palmitoyltransferase I
HMG CoA synthase II
Apolipoprotein A-I
Control genes involved in 
the metabolism of lipids, 
lipoproteins
Regulation fatty acid β oxidation
Fibrates (e.g., clofibrate, 
bezafibrate, fenofibrate)
2. PPAR-β/δ 
or PPAR-δ
Adipose tissue
Skin
Brain
Acyl-CoA oxidase
Carnitine palmitoyltransferase I
Lipid metabolism
Energy balance in various large 
tissues
GW501516
GW0742 (both are in 
clinical trial phase)
3. PPAR-γ Adipose tissue
Macrophage
Lipoprotein lipase Differentiates adipocytes
Fatty acid trapping
Thiazolidinediones (e.g., 
Rosiglitazone, pioglitazone)
HMG CoA-3-Hydroxy 3-Methyl Glutaryl Coenzyme A. PPAR: Peroxisome proliferator-activated receptor
Fig. 1: Metabolic regulation of PPARγ as a nuclear receptor. PPAR: 
Peroxisome proliferated-activated receptor, RXR: Retinoid X 
receptor, LBD: Ligand binding domain, DBD: DNA binding domain, 
PPRE: Peroxisome proliferated response elements, R Pase: RNA 
polymerase, and mRNA: messenger ribonucleic acid
Fig. 2: X-Ray crystal structure of peroxisome proliferator-
activated receptor-gamma (PPAR-γ) heterodimer with retinoid X 
receptor (RXR). PPAR-γ in red color and RXR in blue
was potential lead to enlighten the discovery of other TZDs as PPAR-γ 
agonist. Drug-induced liver failure was the main concern about 
prototype TRO being removed from the market in 2000. Pioglitazone 
and Rosiglitazone are the two agents approved in 1999 and still available 
in the market as insulin sensitizer of TZD [45]. Despite some adverse 
42
Asian J Pharm Clin Res, Vol 10, Issue 12, 2017, 40-44
 Bairy 
effects, constant clinical investigation supported significant glycemic 
improvement potency of them. However, extensive monotherapy of this 
class is limited by fluid retention and other toxicities (cardiac, skeletal 
muscle, renal and bone marrow) [46-48]. Edema and weight gain 
contribute the major adverse effects of glitazones and established facts 
suggest that heart affects the most in human and other experimental 
animals. Although in terms of potential affinity, pioglitazone has less 
activity toward cardiac tissue than rosiglitazone.
Drug development of PPAR- γ ligands toward insulin resistance
Endogenous ligands for PPAR-γ include free fatty acids, oxidized plasma 
lipoproteins, eicosanoids, some polyunsaturated fatty acids (mainly 
DHA and EPA) and platelet activating factors [49]. A wide number of 
natural as well as synthetic exogenous ligands (Table 2) were discovered 
and developing on clinical stages targeting PPAR-γ to improve insulin 
resistance in human. TZDs are the synthetic ligands for agonism of 
nuclear receptor PPAR-γ. Starting with TRO to Balaglitazone [50,51] 
new glitazones are developing, but some are failing at various phases of 
clinical investigation as they associated with various toxicities. Non-TZD 
agonist (GW2570) [52] also developing still nuclear receptor targeted 
agents with strong efficacy and less toxicity is a major challenge 
to research community. To overcome this problem, new research 
proposals on pipeline to establish partial, dual PPAR (PPAR α/γ and 
PPAR δ/γ) [53] and pan-PPAR [54] agonist which may reduce the 
toxicities by weak specificity toward PPAR-γ without effecting efficacy. 
Here, the list of natural [12,55,56] and synthetic [44,45,52,57,58] 
modulators of PPAR-γ given.
PPAR-γ and other pharmacodynamics
The superfamily of nuclear receptor PPARs especially PPAR-γ is 
associated with other pharmacological attributions. Along with 
combating diabetic condition, they have widely accepted potency for 
obesity as PPAR-γ is highly expressed in adipose tissue. Among two 
different isoforms of PPARγ: PPAR-γ1 and PPAR-γ2, PPARγ2 is adipose 
tissue-specific. They have a lethal effect on adipocyte differentiation 
on the gene responsible for adipocyte lipid-binding protein (aP2), 
phosphoenolpyruvate carboxykinase, acyl-CoA synthase, and 
lipoprotein lipase as well as induce negative signal for other tissues to 
accumulate triglycerides (TG) [59]. Natural anti-inflammatory ligand 
15d-PGJ2 [60] and nonsteroidal anti-inflammatory agents (NSAIDs) 
including ibuprofen, fenoprofen and indomethacin [61] have PPAR-γ 
agonistic effect. These agents induce anti-inflammatory effect by 
targeting PPAR-γ which inhibit production of inflammatory cytokines, 
such as tissue necrosis factor-alpha, interleukin-1 (IL-1) and IL-6, 
known as major contributors of inflammation [59,61]. PPAR-γ is now 
a research hotcake for targeting angiogenesis and studies indicate 
that they not only target the gene responsible for cell division but also 
negatively regulate the cell cycle [62]. TZDs, the synthetic ligands of 
PPAR-γ inhibits the proliferation of malignant cells or antiangiogenic 
for breast adenocarcinoma, prostate carcinoma, colorectal carcinoma, 
non-small cell lung carcinoma, pancreatic carcinoma, bladder cancer, 
gastric carcinoma and glial brain tumors [61-63]. They also have a 
weak binding potential toward those tissues where PPAR-α distributed 
and are used in treating hyperlipidemia in atherosclerosis, reduce 
triglyceride-rich very low-density lipoprotein synthesis in the liver. New 
research agenda trying to establish other pharmacological aspects such 
as autism [64], steatohepatitis [65] and ovarian hyperstimulation [66] 
of PPAR- γ targeting agents.
CONCLUSION
Considering increasing prevalence of glucose intolerance and modern 
lifestyle issue metabolic disorder is a global burden. Besides altering 
day-to-day life energy consumption/ expenditure ratio pharmacon is 
also playing a major role to balance the abnormality of metabolism. 
Nuclear superfamily PPARs are of intense research interest being 
distributed to those tissues responsible for metabolic homeostasis. 
Along with other isoforms, PPAR-γ managing the metabolic prevalence 
such as hyperglycemia, dyslipidemia and atherosclerosis with high hope. 
The main challenging fact of PPAR-γ agonist TZDs is cardiovascular 
risk factors. There remains the prime interest to develop new PPAR-γ 
agonist with promising clinical data. A huge number of enthusiastic 
works ongoing to develop partial as well as a dual agonist with less 
toxicity data and future looks in great urge to control the protein only 
for reducing metabolic worse conditions.
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